NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Mallinckrodt Public Limited Company (: MNK)
Class Period: February 28, 2018 - July 16, 2019
Lead Plaintiff Deadline: September 24, 2019
Join the action: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?wire=3
About the lawsuit: Mallinckrodt Public Limited Company allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the Mallinckrodt Public Limited Company class action contact [email protected].
Cardinal Health, Inc. (: CAH)
Class Period: March 2, 2015 - May 2, 2018
Lead Plaintiff Deadline: September 30, 2019
Join the action: https://www.zlk.com/pslra-1/cardinal-health-inc-loss-form?wire=3
About the lawsuit: Cardinal Health, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; 2) Cordis’s antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis’s inventory balances; 5) Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan"; and 6) to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.
To learn more about the Cardinal Health, Inc. class action contact [email protected].
Granite Construction Incorporated (: GVA)
Class Period: October 26, 2018 - August 1, 2019
Lead Plaintiff Deadline: October 15, 2019
Join the action: https://www.zlk.com/pslra-1/granite-construction-incorporated-loss-form?wire=3
About the lawsuit: Granite Construction Incorporated allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an “untenable” imbalance of risk sharing between the Company and the joint venture project owners; (3) as a result, the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the Granite Construction Incorporated class action contact [email protected].
Sarepta Therapeutics, Inc. ( SRPT)
Class Period: September 6, 2017 - August 19, 2019
Lead Plaintiff Deadline: October 29, 2019
Join the action: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, Sarepta Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
To learn more about the Sarepta Therapeutics, Inc. class action contact [email protected].
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
